Gabriella E Wilson, James Knight, Qing Liu, Ashish Shelar, Emma Stewart, Xiaomei Wang, Xiting Yan, Joshua Sanders, Cynthia Visness, Michelle Gill, Rebecca Gruchalla, Andrew H Liu, Meyer Kattan, Gurjit K Khurana Hershey, Alkis Togias, Patrice M Becker, Matthew C Altman, William W Busse, Daniel J Jackson, Ruth R Montgomery, Geoffrey L Chupp
BACKGROUND: MUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-interleukin-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma. Despite this reduction in eosinophilia, exacerbation risk persisted in certain patients treated with mepolizumab. This raises the possibility that subpopulations of airway eosinophils exist that contribute to breakthrough exacerbations. OBJECTIVE: Determine the effect of mepolizumab on airway eosinophils in childhood asthma...
March 12, 2024: Journal of Allergy and Clinical Immunology